Novel therapeutics in rare genetic obesities: A narrative review

Beatrice Dubern; Nathan Faccioli; Christine Poitou; Karine Clément

doi:10.1016/j.phrs.2023.106763

Novel therapeutics in rare genetic obesities: A narrative review

Pharmacol Res. 2023 May:191:106763. doi: 10.1016/j.phrs.2023.106763. Epub 2023 Apr 8.

Authors

Beatrice Dubern¹, Nathan Faccioli², Christine Poitou³, Karine Clément³

Affiliations

¹ Assistance Publique Hôpitaux de Paris, Trousseau Hospital, Pediatric Nutrition and Gastroenterology Department, French Reference Center for Prader-Willi Syndrome and other rare obesities (PRADORT), Paris, France; Systemic approaches, NutriOmics research group, 75013 Paris, France; Sorbonne Université, INSERM, Nutrition and obesities, NutriOmics research group, 75013 Paris, France. Electronic address: beatrice.dubern@aphp.fr.
² Assistance Publique Hôpitaux de Paris, Trousseau Hospital, Pediatric Nutrition and Gastroenterology Department, French Reference Center for Prader-Willi Syndrome and other rare obesities (PRADORT), Paris, France; Systemic approaches, NutriOmics research group, 75013 Paris, France; Sorbonne Université, INSERM, Nutrition and obesities, NutriOmics research group, 75013 Paris, France.
³ Assistance Publique Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Nutrition Department, Paris, France; Systemic approaches, NutriOmics research group, 75013 Paris, France; Sorbonne Université, INSERM, Nutrition and obesities, NutriOmics research group, 75013 Paris, France.

PMID: 37037398
DOI: 10.1016/j.phrs.2023.106763

Abstract

The better understanding of the molecular causes of rare genetic obesities and its associated phenotype involving the hypothalamus allows today to consider innovative therapeutics focused on hunger control. Several new pharmacological molecules benefit patients with monogenic or syndromic obesity. They are likely to be among the treatment options for these patients in the coming years, helping clinicians and patients prevent rapid weight progression and eventually limit bariatric surgery procedures, which is less effective in these patients. Their positioning in the management of such patients will be needed to be well defined to develop precision medicine in genetic forms of obesity.

Keywords: Childhood obesity; Genetics; Hypothalamus; Melanocortins; Monogenic obesity.

Publication types

Review

MeSH terms

Bariatric Surgery*
Humans
Obesity* / drug therapy
Obesity* / genetics